“筋骨并重”视阈下鸢尾素对肌骨衰减的异病同治作用

刘晏东; 邓强; 李中锋; 彭冉东; 王雨榕; 杨镇源; 郭铁峰; 罗林钊

doi:10.14148/j.issn.1672-0482.2023.0613

“筋骨并重”视阈下鸢尾素对肌骨衰减的异病同治作用

doi: 10.14148/j.issn.1672-0482.2023.0613

1.
甘肃中医药大学中医临床学院, 甘肃兰州 730000
2.
甘肃省中医院脊柱疾病诊疗中心, 甘肃兰州 730050

基金项目:

中央财政转移支付地方项目 20210200111

国家中医药管理局国家中医临床研究基地业务建设科研专项课题 JDZX2015039

兰州市科技计划项目 2022-3-30

详细信息

作者简介:
刘晏东, 男, 住院医师, E-mail: 1327171163@qq.com

通讯作者:
邓强, 男, 主任医师, 主要从事中西医结合防治骨科疾病的研究, E-mail: 2959183478@qq.com

中图分类号: R274.9
计量
- 文章访问数: 84
- HTML全文浏览量: 14
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-13
- 网络出版日期: 2023-07-15
- 发布日期: 2023-07-10

Exploring Effects of Irisin on Musculoskeletal Decay Based on Equal Emphasis on Sinews and Bones and Same Treatment for Different Diseases Theories

1.
Clinical College of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
2.
Spinal Disease Diagnosis and Treatment Center, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China

摘要

摘要: 骨骼和骨骼肌通过多种渠道相互串扰, 共同组成机体最大的生物运动组织——肌肉骨骼系统。鸢尾素是一种由运动介导的激素样肌因子, 具有同时调节肌再生和骨稳态的双重功能。基于“筋骨并重”及“异病同治”理论, 从中西医两个维度出发, 深入探析鸢尾素对肌肉及骨骼衰减病变的双重治疗作用, 以期为肌骨共病的基础研究和临床防治提供新导向。
- 筋骨并重 /
- 异病同治 /
- 鸢尾素 /
- 肌肉 /
- 骨骼 /
- 肌骨衰减
Abstract: Skeleton and skeletal muscle cross talk with each other through various channels, and together form the largest biological movement tissue of the body, the musculoskeletal system. Irisin is a kind of hormone-like muscle factor mediated by exercise, which has dual functions of simultaneously regulating muscle regeneration and bone homeostasis. Based on the theories of "equal emphasis on sinews and bones" and "same treatment for different diseases ", this study explores the dual therapeutic effects of irisin on musculoskeletal decay lesions from the perspectives of traditional Chinese medicine and Western medicine, in order to provide new directions for basic research and clinical prevention and treatment of muscle and bone comorbidities.
- equal emphasis on sinews and bones /
- same treatment for different diseases /
- irisin /
- muscle /
- bone /
- musculoskeletal decay

HTML全文

参考文献(44)

[1]	LASKOU F, FUGGLE NR, PATEL HP, et al. Associations of osteoporosis and sarcopenia with frailty and multimorbidity among participants of the Hertfordshire Cohort Study[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 220-229. doi: 10.1002/jcsm.12870
[2]	YU C, DU YJ, PENG Z, et al. Research advances in crosstalk between muscle and bone in osteosarcopenia[J]. Exp Ther Med, 2023, 25(4): 189. doi: 10.3892/etm.2023.11888
[3]	BOUTIN RD, LENCHIK L. Value-added opportunistic CT: Insights into osteoporosis and sarcopenia[J]. AJR Am J Roentgenol, 2020, 215(3): 582-594. doi: 10.2214/AJR.20.22874
[4]	巢元方. 诸病源候论[M]. 北京: 中国中医药出版社, 2011: 278-281. CHAO YF. The Theory of Various Diseases and Their Origins[M]. Beijing: China press of traditional Chinese medicine, 2011: 278-281.
[5]	秦大平, 张晓刚, 宋敏, 等. 从筋骨并重理论探讨肌少症与骨质疏松症的中医药防治策略[J]. 中华中医药杂志, 2019, 34(9): 4364-4369. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201909124.htm QIN DP, ZHANG XG, SONG M, et al. Discussion on the prevention and treatment strategy of sarcopenia and osteoporosis with traditional Chinese medicine based on the theory of muscles and bones[J]. China J Tradit Chin Med Pharm, 2019, 34(9): 4364-4369. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201909124.htm
[6]	LARA-CASTILLO N, JOHNSON ML. Bone-muscle mutual interactions[J]. Curr Osteoporos Rep, 2020, 18(4): 408-421. doi: 10.1007/s11914-020-00602-6
[7]	ZHOU BN, ZHANG Q, LIN XY, et al. The roles of sclerostin and irisin on bone and muscle of orchiectomized rats[J]. BMC Musculoskelet Disord, 2022, 23(1): 1049. doi: 10.1186/s12891-022-05982-7
[8]	LIU SQ, CUI FQ, NING KT, et al. Role of irisin in physiology and pathology[J]. Front Endocrinol, 2022, 13: 962968. doi: 10.3389/fendo.2022.962968
[9]	黄元御. 四圣心源[M]. 北京: 中国科学技术出版社, 2019: 139-143. HUANG YY. The Four Sages Study[M]. Beijing: China science and technology press, 2019: 139-143.
[10]	张啸宇, 李敬池, 王楠, 等. "筋骨并重"理论指导下腰背肌锻炼降低PTED术后邻椎病风险力学机制的研究[J]. 中国中西医结合杂志, 2021, 41(6): 695-700. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202106014.htm ZHANG XY, LI JC, WANG N, et al. Study on the biomechanical mechanism of paraspinal muscles exercise to reduce the risk of adjacent segment disease after percutaneous transforaminal endoscopic discectomy guided by "paying equal attention to sinew and bone"[J]. Chin J Integr Tradit West Med, 2021, 41(6): 695-700. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202106014.htm
[11]	刘斌, 苏晓川, 滕军燕. 中西医结合治疗骨折原则的新启示[J]. 中华中医药杂志, 2020, 35(10): 4804-4807. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202010010.htm LIU B, SU XC, TENG JY. New enlightenment on the rule of integration of traditional Chinese and western medicine in the treatment of fractures[J]. China J Tradit Chin Med Pharm, 2020, 35(10): 4804-4807. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202010010.htm
[12]	吴谦. 医宗金鉴[M]. 北京: 中国中医药出版社, 1994: 355-369. WU Q. The Golden Mirror of Medicine[M]. Beijing: China press of traditional Chinese medicine, 1994: 355-369.
[13]	王国军. "筋骨并重"理念在骨科疾病中的应用[J]. 江苏中医药, 2019, 51(11): 41-44. doi: 10.3969/j.issn.1672-397X.2019.11.015 WANG GJ. The application of "equal value of both tendon and bone" in the treatment to orthopaedics diseases[J]. Jiangsu J Tradit Chin Med, 2019, 51(11): 41-44. doi: 10.3969/j.issn.1672-397X.2019.11.015
[14]	黄帝内经灵枢[M]. 北京: 人民卫生出版社, 2015: 151-152. The Yellow Emperor's Canon of Internal Medicine: Lingshu[M] Beijing: People's medical publishing house, 2015: 151-152.
[15]	路翀, 郑浩, 杨鸫祥, 等. 基于"脾肾相关"理论探讨鸢尾素在肌少-骨质疏松症中的作用机制[J]. 中国骨质疏松杂志, 2022, 28(10): 1507-1513. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202210019.htm LU C, ZHENG H, YANG DX, et al. Exploration of the mechanism of irisin in sarcopenia-osteopenia based on the spleen-kidney correlation theory[J]. Chin J Osteoporos, 2022, 28(10): 1507-1513. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202210019.htm
[16]	YANG JY, JIANG T, XU GM, et al. Bibliometrics analysis and visualization of sarcopenia associated with osteoporosis from 2000 to 2022[J]. J Pain Res, 2023, 16: 821-837. doi: 10.2147/JPR.S403648
[17]	SALAMANNA F, CONTARTESE D, RUFFILLI A, et al. Sharing circulating micro-RNAs between osteoporosis and sarcopenia: A systematic review[J]. Life, 2023, 13(3): 602. doi: 10.3390/life13030602
[18]	PICKERING ME. Cross-talks between the cardiovascular disease-sarcopenia-osteoporosis triad and magnesium in humans[J]. Int J Mol Sci, 2021, 22(16): 9102. doi: 10.3390/ijms22169102
[19]	桑继亮, 杨岩冰, 马江涛, 等. 基于PI3K/Akt/FoxO3a信号通路探讨壮骨止痛胶囊防治肌少-骨质疏松症的作用机制[J]. 中医药信息, 2022, 39(10): 19-27. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN202210004.htm SANG JL, YANG YB, MA JT, et al. Mechanism of Zhuanggu Zhitong capsule in preventing and treating osteosarcopenia based on PI3K/akt/FoxO3a signaling pathway[J]. Inf Tradit Chin Med, 2022, 39(10): 19-27. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN202210004.htm
[20]	BAO JF, SHE QY, HU PP, et al. Irisin, a fascinating field in our times[J]. Trends Endocrinol Metab, 2022, 33(9): 601-613. doi: 10.1016/j.tem.2022.06.003
[21]	MAAK S, NORHEIM F, DREVON CA, et al. Progress and challenges in the biology of FNDC5 and irisin[J]. Endocr Rev, 2021, 42(4): 436-456. doi: 10.1210/endrev/bnab003
[22]	POLYZOS SA, ANASTASILAKIS AD, EFSTATHIADOU ZA, et al. Irisin in metabolic diseases[J]. Endocrine, 2018, 59(2): 260-274. doi: 10.1007/s12020-017-1476-1
[23]	LIU JS, QI BT, GAN L, et al. A bibliometric analysis of the literature on irisin from 2012-2021[J]. Int J Environ Res Public Heath, 2022, 19(10): 6153. doi: 10.3390/ijerph19106153
[24]	KORTA P, POCHEC EW, MAZUR-BIAŁYA. Irisin as a multifunctional protein: Implications for health and certain diseases[J]. Medicina, 2019, 55(8): 485. doi: 10.3390/medicina55080485
[25]	FLORI L, TESTAI L, CALDERONE V. The irisin system: From biological roles to pharmacological and nutraceutical perspectives[J]. Life Sci, 2021, 267: 118954. doi: 10.1016/j.lfs.2020.118954
[26]	ZHU X, LI X, WANG X, et al. Irisin deficiency disturbs bone metabolism[J]. J Cell Physiol. 2021, 236(1): 664-676. doi: 10.1002/jcp.29894
[27]	CHANG JS, KIM TH, NGUYEN TT, et al. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study[J]. Geriatr Gerontol Int, 2017, 17(11): 2266-2273. doi: 10.1111/ggi.13030
[28]	WU YX, WU YX, YU J, et al. Irisin ameliorates D-galactose-induced skeletal muscle fibrosis via the PI3K/Akt pathway[J]. Eur J Pharmacol, 2023, 939: 175476. doi: 10.1016/j.ejphar.2022.175476
[29]	WANG YW, GU YQ, HUANG J, et al. Serum vitamin D status and circulating irisin levels in older adults with sarcopenia[J]. Front Nutr, 2022, 9: 1051870. doi: 10.3389/fnut.2022.1051870
[30]	KONISHI M, ISHIDA J, SAITO M, et al. Irisin—a myokine potentially bridging muscle and fat tissue in cachexia[J]. J Cachexia Sarcopenia Muscle, 2015, 6(4): 396-397. doi: 10.1002/jcsm.12085
[31]	GUO M, YAO J, LI J, et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction[J]. J Cachexia Sarcopenia Muscle, 2023, 14(1): 391-405. doi: 10.1002/jcsm.13141
[32]	D'AMURI A, SANZ JM, LAZZER S, et al. Irisin attenuates muscle impairment during bed rest through muscle-adipose tissue crosstalk[J]. Biology, 2022, 11(7): 999. doi: 10.3390/biology11070999
[33]	WU YX, WU YX, YU J, et al. Irisin ameliorates D-galactose-induced skeletal muscle fibrosis via the PI3K/Akt pathway[J]. Eur J Pharmacol, 2023, 939: 175476. doi: 10.1016/j.ejphar.2022.175476
[34]	TIANO JP, SPRINGER DA, RANE SG. SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) during exercise[J]. J Biol Chem. 2015, 290(12): 7671-84. doi: 10.1074/jbc.M114.617399
[35]	COLAIANNI G, STORLINO G, SANESI L, et al. Myokines and osteokines in the pathogenesis of muscle and bone diseases[J]. Curr Osteoporos Rep, 2020, 18(4): 401-407. doi: 10.1007/s11914-020-00600-8
[36]	XUE Y, HU SH, CHEN CC, et al. Myokine Irisin promotes osteogenesis by activating BMP/SMAD signaling via αV integrin and regulates bone mass in mice[J]. Int J Biol Sci, 2022, 18(2): 572-584. doi: 10.7150/ijbs.63505
[37]	COLAIANNI G, CUSCITO C, MONGELLI T, et al. The myokine irisin increases cortical bone mass[J]. Proc Natl Acad Sci USA, 2015, 112(39): 12157-12162. doi: 10.1073/pnas.1516622112
[38]	ALBRECHT E, NORHEIM F, THIEDE B, et al. Irisin—a myth rather than an exercise-inducible myokine[J]. Sci Rep, 2015, 5: 8889. doi: 10.1038/srep08889
[39]	ZERLOTIN R, ORANGER A, PIGNATARO P, et al. Irisin and secondary osteoporosis in humans[J]. Int J Mol Sci, 2022, 23(2): 690. doi: 10.3390/ijms23020690
[40]	XU LL, SHEN LY, YU XL, et al. Effects of irisin on osteoblast apoptosis and osteoporosis in postmenopausal osteoporosis rats through upregulating Nrf2 and inhibiting NLRP3 inflammasome[J]. Exp Ther Med, 2020, 19(2): 1084-1090.
[41]	BEHERA J, ISON J, VOOR MJ, et al. Exercise-linked skeletal irisin ameliorates diabetes-associated osteoporosis by inhibiting the oxidative damage-dependent miR-150-FNDC5/pyroptosis axis[J]. Diabetes, 2022, 71(12): 2777-2792. doi: 10.2337/db21-0573
[42]	MA YX, QIAO XY, ZENG RJ, et al. Irisin promotes proliferation but inhibits differentiation in osteoclast precursor cells[J]. FASEB J, 2018, 32(11): 5813-5823. doi: 10.1096/fj.201700983RR
[43]	ESTELL EG, LE PT, VEGTING Y, et al. Irisin directly stimulates osteoclastogenesis and bone resorption in vitro and in vivo[J]. Elife, 2020, 9: e58172. doi: 10.7554/eLife.58172
[44]	祁亮, 莫亮, 卫杨文祥, 等. 骨质疏松症和动脉粥样硬化机制及"异病同治"分析[J]. 中国骨质疏松杂志, 2023, 29(2): 215-220, 231. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202302012.htm QI L, MO L, WEI YWX, et al. Analysis of mechanisms between osteoporosis and atherosclerosis with concept of "simultaneous treatment of different diseases"[J]. Chin J Osteoporos, 2023, 29(2): 215-220, 231. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202302012.htm